First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes: an exploratory analysis of immune biomarkers

First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes: an exploratory analysis of immune biomarkers

Abstract Background IMCY-0098, a synthetic peptide developed to halt disease progression via elimination of key immune cells in the autoimmune cascade, has shown a promising safety profile for the treatment of type 1 diabetes (T1D) in a recent phase 1b trial. This exploratory analysis of data from t...

Full description

Bibliographic Details
Main Authors: Jean Van Rampelbergh, Peter Achenbach, Richard David Leslie, Martin Kindermans, Frédéric Parmentier, Vincent Carlier, Nicolas Bovy, Luc Vanderelst, Marcelle Van Mechelen, Pierre Vandepapelière, Christian Boitard
Format: Article
Language:English
Published: BMC 2024-06-01
Series:BMC Medicine
Subjects:
Type 1 diabetes
Immunotherapy
T cells
Beta cells
Exploratory analysis
Immune biomarker machine learning
Online Access:https://doi.org/10.1186/s12916-024-03476-y

Internet

https://doi.org/10.1186/s12916-024-03476-y

Similar Items